Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases
US-2024246901-A1 · Jul 25, 2024 · US
US9758477B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9758477-B2 |
| Application number | US-201514975239-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 18, 2015 |
| Priority date | Jul 1, 2011 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, at least one compound of formula (III): wherein: R 10 is selected from the group consisting of H, CH 3 , Cl and Br; R y is selected from the group consisting of or a pharmaceutically acceptable salt thereof, and at least one additional agent that treats Hepatitis B virus (HBV) infection. 2. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, at least one compound selected from the group consisting of: 3-(Azepane-1-sulfonyl)-N-benzyl-4-chloro-benzamide, N-Benzyl-4-chloro-3-(piperidine-1-sulfonyl)-benzamide, N-Benzyl-4-methyl-3-(4-methyl-piperidine-1-sulfonyl)-benzamide, N-Benzyl-3-benzylsulfamoyl-4-methyl-benzamide, 3-(3-Benzylcarbamoyl-benzenesulfonylamino)-benzoic acid, N-Benzyl-4-bromo-3-diethylsulfamoyl-benzamide, any pharmaceutically acceptable salt thereof, and any mixtures thereof; and at least one additional agent that treats Hepatitis B virus (HBV) infection.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for RNA viruses · CPC title
for DNA viruses · CPC title
1,4-Oxazines, e.g. morpholine · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.